RenovoRx (RNXT) Income from Continuing Operations (2020 - 2026)
RenovoRx (RNXT) posted Income from Continuing Operations of 3482000.0 for Q1 2026, up 1.14% sequentially from 3522088.0 in Q4 2025, and down 1.66% YoY from 3540929.33 in Q1 2025.
RenovoRx (RNXT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
RenovoRx has reported Income from Continuing Operations for 7 years, with the latest figure at 3482000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 1.66% year-over-year to 3482000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14732088.0 (up 49.53% YoY) and the FY2025 annual result came in at 32310000.0, down 16.42% from the prior year.
- Income from Continuing Operations improved to 3482000.0 in Q1 2026 per RNXT's latest filing, from 3522088.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2725000.0 in Q4 2023 and troughed at 19416000.0 in Q4 2024.
- A 5-year average of 4484064.0 and a median of 3425000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 612.51% in 2024, then jumped 81.86% in 2025.
- Over 5 years, Income from Continuing Operations stood at 3098000.0 in 2022, then rose by 12.04% to 2725000.0 in 2023, then slumped by 612.51% to 19416000.0 in 2024, then surged by 81.86% to 3522088.0 in 2025, then grew by 1.14% to 3482000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3482000.0, 3522088.0, and 4061000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | -3.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.77 Mn |
| Mar 31, 2026 | -3.48 Mn |
| Dec 31, 2025 | -3.52 Mn |
| Sep 30, 2025 | -4.06 Mn |
| Jun 30, 2025 | -3.67 Mn |
| Mar 31, 2025 | -3.43 Mn |
| Dec 31, 2024 | -19.42 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -3.32 Mn |
| Mar 31, 2024 | -3.02 Mn |
| Dec 31, 2023 | -2.73 Mn |
| Sep 30, 2023 | -3.33 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -5.39 Mn |
| Dec 31, 2022 | -3.10 Mn |
| Sep 30, 2022 | -2.88 Mn |
| Jun 30, 2022 | -3.33 Mn |
| Mar 31, 2022 | -4.31 Mn |
| Dec 31, 2021 | -1.62 Mn |
| Sep 30, 2021 | -5.21 Mn |